Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
InnoCare Pharma Ltd. ( (HK:9969) ) has provided an update.
InnoCare Pharma Ltd. announced positive results from a Phase IIb clinical trial of orelabrutinib for systemic lupus erythematosus (SLE), leading to the approval of a Phase III trial. The Phase IIb trial demonstrated significant efficacy and safety, with orelabrutinib showing a statistically significant improvement in SLE response rates compared to placebo. The initiation of the Phase III trial marks a significant step in the development of orelabrutinib as a first-in-class oral BTK inhibitor for SLE, potentially enhancing InnoCare’s position in the autoimmune disease treatment market.
The most recent analyst rating on (HK:9969) stock is a Hold with a HK$19.60 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company focused on developing innovative therapies for autoimmune diseases. Their primary product, orelabrutinib, is a Bruton’s Tyrosine Kinase (BTK) inhibitor, which is being developed for conditions such as systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), and multiple sclerosis (MS). The company retains rights for SLE and other autoimmune indications in Greater China and Southeast Asia, while international rights have been licensed to Zenas.
Average Trading Volume: 10,910,801
Technical Sentiment Signal: Buy
Current Market Cap: HK$21.33B
For a thorough assessment of 9969 stock, go to TipRanks’ Stock Analysis page.